Effect of fluvastatin on cardiac outcomes in kidney transplant Patients with systemic lupus erythematosus a randomized placebo-controlled study

Arthritis and Rheumatism

Volumn 60, Issue 4, 2009, Pages 1060-1064

  Norby, Gudrun E ^a   Holme, Ingar ^b   Fellström, Bengt ^c   Jardine, Alan ^d   Cole, Edward ^e   Abedini, Sadollah ^a   Holdaas, Hallvard ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d WESTERN INFIRMARY   (United Kingdom)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; KIDNEY TRANSPLANTATION; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; FATTY ACIDS, MONOUNSATURATED; FOLLOW-UP STUDIES; HUMANS; INDOLES; KAPLAN-MEIERS ESTIMATE; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; MORBIDITY; MYOCARDIAL INFARCTION; PLACEBOS; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 65249180649     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24379     Document Type: Article

References (17)

1. Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159-67.
2. Stone JH. End-stage renal disease in lupus: disease activity, dialysis, and the outcome of transplantation. Lupus 1998;7:654-9.
3. Moroni G, Tantardini F, Gallelli B, Quaglini S, Banfi G, Poli F, et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis 2005;45:903-11.
4. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005;5:2929-36.
5. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-15.
6. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
7. Bruce IN. Atherogenesis and autoimmune disease: the model of lupus. Lupus 2005;14:687-690.
8. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
10. Costenbader KH, Karlson EW, Gall V, de Pablo P, Finckh A, Lynch M, et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum 2005;53:718-23.
11. Petri M, Kiani AN, Post W, Magder L. Lupus Atherosclerosis Prevention Study (LAPS) : a randomized double blind placebo controlled trial of atorvastatin versus placebo [abstract]. Arthritis Rheum 2006;54 Suppl 9:S520.
12. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 2007;46:1560-5.
13. Schanberg LE, Sandborg C. Dyslipoproteinemia and premature atherosclerosis in pediatric systemic lupus erythematosus. Curr Rheumatol Rep 2004;6:425-33.
14. Fortin PR, Abrahamowicz M, Cymet A, Neville C, Harvey P, Su J, et al. The Health Improvement and Prevention Program (HIPP) in systemic lupus erythematosus shows preliminary benefits in reducing the estimated 8-year risk of cardiovascular disease [abstract]. Arthritis Rheum 2006;54 Suppl 9:S791.
15. Bruce IN. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005;44: 1492-502.
16. Toloza S, Urowitz MB, Gladman DD. Should all patients with systemic lupus erythematosus receive cardioprotection with statins? Nat Clin Pract Rheumatol 2007;3:536-7.
17. Costenbader KH, Liang MH, Chibnik LB, Aizer J, Kwon H, Gall V, et al. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 2007;27:1071-7.9